Abiopharma

New Form 8-K - ProPhase Labs, Inc. Filed: 2025-08-28 AccNo: 0001493152-25-012414 Size: 222 KB Item 1.02: Termination of a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

New Form 6-K - GSK plc Filed: 2025-08-28 AccNo: 0001654954-25-010110 Size: 3 MB

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT, 2016

New Form EFFECT - IM Cannabis Corp. Filed: 2025-08-27 AccNo: 9999999995-25-002760 Size: 1 KB

New Form EFFECT - CARGO Therapeutics, Inc. Filed: 2025-08-27 AccNo: 9999999995-25-002754 Size: 1 KB

New Form EFFECT - CARGO Therapeutics, Inc. Filed: 2025-08-27 AccNo: 9999999995-25-002752 Size: 1 KB

Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference

FDA approve CLINDAMYCIN PHOSPHATE

FDA approve DESMOPRESSIN ACETATE

FDA approve LIDOCAINE HYDROCHLORIDE

FDA approve DOXYCYCLINE HYCLATE

FDA approve MACITENTAN

FDA approve CLINDAMYCIN PHOSPHATE

FDA approve CLINDAMYCIN PHOSPHATE

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016